跳至主要内容
临床试验/NCT02143492
NCT02143492已完成不适用

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Argos Therapeutics0 个研究点目标入组 11 人开始时间: 2013年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
11
主要终点
Tumor Specimen

研究概览

简要总结

Standard treatment for kidney cancer is to remove the tumors from the body with surgery. The purpose of this clinical trial is to collect, preserve, and store excess kidney cancer tumor specimens that would normally be discarded after surgery.

详细描述

The purpose of this non-treatment, non-interventional protocol is to collect, preserve, and store excess tumor specimens, which would otherwise be discarded, following routine nephrectomy for subjects with advanced renal cell carcinoma (RCC). The collected tumor specimen will be preserved under current Good Manufacturing Practice conditions and will not be used for any other research or therapeutic purpose without a separate consent from the subject, specific to the intended use on a separate Institutional Review Board or Institutional Ethics Committee approved Argos sponsored study.

Following routine nephrectomy (partial or cytoreductive) as indicated for subjects with advanced RCC, small samples of the excised tumor will be sectioned and placed into an RNA preservative solution as supplied by the sponsor. After collection, this preserved tumor specimen will be shipped to a repository operating under current Good Manufacturing Practice conditions. The tumor specimen will be stored for no longer than five years unless subsequent consent is obtained for extended storage or other use.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Diagnosis or clinical signs of advanced RCC (Stage III or IV RCC; Refer to Appendix A)
  • Scheduled for cytoreductive or partial (unilateral or bilateral) nephrectomy
  • Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of tumor specimen collection prior to enrollment

排除标准

  • Evidence of brain metastases prior to nephrectomy
  • Requirement for systemic chronic immunosuppressive drugs or systemic chronic corticosteroids, for active autoimmune disorder(s) or other conditions (e.g.: rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, organ transplant recipient, etc.)
  • History of HIV infection, or history of chronic infection with Hepatitis B or Hepatitis C

结局指标

主要结局

Tumor Specimen

时间窗: 5 years

Tumor specimen collection

次要结局

未报告次要终点

研究者

发起方
Argos Therapeutics
申办方类型
Industry
责任方
Sponsor

相似试验